---
title: Individualized brain stimulation improves walking
nct_id: NCT07570212
phase: NA
status: RECRUITING
sponsor: Peking University First Hospital
study_type: INTERVENTIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT07570212"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07570212"
last_fetched: "2026-05-10T14:08:36.116Z"
source: "Parkinson's Pathways (curated)"
---
# Individualized brain stimulation improves walking

**Goal (in five words):** Individualized brain stimulation improves walking

**Official Title:** Exploration of the Efficacy of Individualized Transcranial Magnetic Stimulation in the Treatment of Parkinsonian Disorders

**Trial ID:** [NCT07570212](https://clinicaltrials.gov/study/NCT07570212)

## Key Facts

- **Phase:** NA
- **Status:** RECRUITING
- **Study Type:** INTERVENTIONAL
- **Sponsor:** Peking University First Hospital
- **Target Enrollment:** 50 participants
- **Start Date:** 2025-12-22
- **Completion Date:** 2027-09-22
- **Conditions:** Parkinson's Disease, Multiple System Atrophy, Progressive Supranuclear Palsy
- **Interventions:** TMS
- **Intervention Types:** DEVICE

## Summary For Families

The trial tests whether individualized transcranial magnetic stimulation can reduce motor and related symptoms in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy by targeting the specific brain circuits that are malfunctioning. It delivers focused magnetic pulses guided by each person’s EEG and MRI to change abnormal neural excitability; it does not replace levodopa, but by normalizing circuit activity it may improve response to existing medications and reduce symptoms. The team is enrolling adults 30 to 80 with clinically established or probable PD, MSA, or PSP at moderate stages (PD H‑Y 2,4; MSA UMSARS Part IV 1,4; PSP mRS 2,4) who can consent and follow study procedures. People with metallic implants or pacemakers, a history of epilepsy, MRI or EEG contraindications, current TMS or similar therapies, unstable medical conditions, or certain psychiatric issues are not eligible.

## Eligibility

- **Minimum age:** 30 Years
- **Maximum age:** 80 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

1. Diagnostic Criteria Clinically established or clinically probable Parkinson's Disease (PD) according to the 2015 International Parkinson and Movement Disorder Society (MDS) diagnostic criteria; Clinically established or clinically probable Multiple System Atrophy (MSA) according to the 2022 MDS diagnostic criteria; Clinically probable or clinically possible Progressive Supranuclear Palsy (PSP) according to the 2017 MDS diagnostic criteria.
2. Demographics Aged 30 to 80 years, inclusive; no gender restrictions.
3. Disease Severity and Staging PD: Modified Hoehn and Yahr (H-Y) stage 2-4; MSA: Unified Multiple System Atrophy Rating Scale (UMSARS) Part IV stage 1-4; PSP: Modified Rankin Scale (mRS) grade 2-4.
4. Informed Consent and Compliance Ability to understand and comply with the study requirements and provide written informed consent.

Exclusion Criteria:

1. Contraindications to TMS Presence of intracranial metallic implants or other foreign bodies, including but not limited to cochlear implants, cardiac pacemakers, or internal metallic/magnetic fragments.
2. Contraindications to EEG and MRI EEG: Known allergy to conductive paste or other EEG-related contraindications. MRI: History of claustrophobia, presence of MRI-incompatible implants, or extensive tattoos.
3. Concurrent Physical Therapies Currently receiving Transcranial Magnetic Stimulation (TMS) or other therapeutic physical modalities, such as Transcranial Direct Current Stimulation (tDCS).
4. Unstable Medical Conditions Presence of unstable systemic diseases requiring urgent pharmacological or surgical intervention.
5. Neurological and Psychiatric History Personal or family history of epilepsy; History of moderate-to-severe psychiatric or psychological disorders; Chronic insomnia or regular use of sedative-hypnotics; Current use of medications that significantly alter central nervous system excitability.
```

## Locations (1)

- Peking University First Hospital, Beijing, Beijing Municipality, China _(39.9075, 116.3972)_
  - Ronghui Yu — (CONTACT) — +8613466379791 — bdyyec@163.com
  - Luhua Wei, M.D. — (SUB_INVESTIGATOR)
  - Zhaoxia Wang, M.D. — (PRINCIPAL_INVESTIGATOR)

## Central Contacts

- Luhua Wei, M.D. — (CONTACT) — +8615120079081 — weiluhua2008@outlook.com
- Kai Li, M.D. — (CONTACT) — +8613511017809 — kaili_neurologist@hotmail.com

---

*Canonical: https://parkinsonspathways.com/trial/NCT07570212*  
*HTML version: https://parkinsonspathways.com/trial/NCT07570212*  
*Source data: https://clinicaltrials.gov/study/NCT07570212*